Premium
POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R 2 ) VS RITUXIMAB/PLACEBO (AUGMENT)
Author(s) -
Thieblemont C.,
Leonard J.,
Trneny M.,
Izutsu K.,
Fowler N.,
Hong X.,
Zhang H.,
Offner F.,
Scheliga A.,
Nowakowski G.,
Pinto A.,
Re F.,
Fogliatto L.,
Scheinberg P.,
Flinn I.,
Moreira C.,
Czuczman M.,
Kalambakas S.,
Fustier P.,
Wu C.,
Gribben J.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.41_2630
Subject(s) - rituximab , medicine , lenalidomide , placebo , post hoc analysis , gastroenterology , univariate analysis , clinical endpoint , neutropenia , lymphoma , multiple myeloma , multivariate analysis , randomized controlled trial , pathology , chemotherapy , alternative medicine